- PROFESSOR EMERITUS Microbiology
MD, New York University
virology, immunology, immunotherapeutic intervention
Resistance to most virus infections is mediated by specific antibody,\r\nthe usual target of most virus vaccines. On the other hand, the recovery\r\nprocess after infection has already occurred is primarily due to cellular\r\nimmune mechanisms which involve cytotoxic lymphocytes which destroy infected\r\ncells preventing further spread of infection and lymphocytes which secrete\r\ncytokines capable of inhibiting virus replication.\r\n\r\n
In collaboration with Dr. Thomas Moran, we are interested in exploring\r\nmodels of immunotherapeutic intervention in experimental virus infections\r\nof mice. In one of these, we use bispecific antibodies to target cytolytic\r\nand/or cytokine secreting lympho- cytes to sites of infection to interrupt\r\nvirus replication and hasten recovery.\r\n\r\n
In another model, we use cytokine (IL-4, IL-10, IL-12) to modulate the\r\nimmune response to dissect the role of various cytokines in the recovery\r\nprocess and to "push" the immune response in the direction of\r\none which is beneficial to the host (virus clearance) instead of one which\r\ncontributes to immunopathology (host responses which are part of the disease\r\npicture).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Schulman is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.